Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Viridian Therapeutics, Inc.

< Previous 1 2 Next >
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society
From Viridian Therapeutics, Inc.
Via Business Wire
Tickers VRDN
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback